




U.S. Food and Drug Administration



CENTER FOR DRUG EVALUATION AND RESEARCH

[FDA Home Page](#) | [CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)

[CDER Home](#)

[About CDER](#)

[Drug Information](#)

[Regulatory Guidance](#)

[CDER Calendar](#)

[Specific Audiences](#)

[CDER Archives](#)

Search



This Guidance has been Updated or Removed

[International Conference on Harmonisation -Safety](#)

S1C(R) Guidance on Dose Selection for Carcinogenicity Studies of Pharmaceuticals and Guidance for Industry: S1C(R) Addendum to Dose Selection for Carcinogenicity Studies of Pharmaceuticals: Addition of a Limit Dose and Related Notes

Have been revised:

Please see: S1C(R) Guidance on Dose Selection for Carcinogenicity Studies of Pharmaceuticals [[PDF](#)]



[Back to Top](#)



[Back to Guidance Page](#)



PDF requires the free [Adobe Acrobat Reader](#)

Date created: September 17, 2008

[CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)
[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [Privacy](#) | [Accessibility](#) | [HHS Home Page](#)

FDA/Center for Drug Evaluation and Research